Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis.
We have established an experimental murine model to gain insight into the pathogenicity and clinical features of type IV group B streptococcus (GBS) infections. Adult CD-1 mice were challenged intravenously with 10(7) type IV GBS cells, inducing systemic invasion. Most of the animals were able to clear the infection from the blood, brain, and lungs within 2 weeks and from the spleen and liver within 1 month. However, the animals were unable to clear the microorganism from the joints and kidneys during the 60-day observation period. About 80% of the mice challenged intravenously with type IV GBS manifested early septic arthritis, which evolved from an acute exudative synovitis to permanent lesions characterized by irreversible joint damage and ankylosis. Induction of persistent septic arthritis was dependent on the number and viability of microorganisms inoculated and was unrelated to the strain of type IV GBS and the growth phase of the inoculum. Type-specific antibodies of both immunoglobulin M and G classes could be detected by agglutination and enzyme-linked immunosorbent assay from days 7 and 14, respectively; immunoglobulin G antibodies persisted for more than 40 days. Complexes of antibodies and group- and type-specific antigens were detected in mouse sera 24 h after infection and persisted up to day 22. These results were obtained an experimental model of type IV GBS chronic infection with early development of septic arthritis, which could be useful in future studies of pathogenicity and immune mechanisms involved in the host resistance to this microorganism.
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
L
L
Tissi
P
P
Marconi
P
P
Mosci
L
L
Merletti
P
P
Cornacchione
E
E
Rosati
S
S
Recchia
C
C
von Hunolstein
G
G
Orefici
D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001170:Arthritis, Infectious / Q000150:complications / Q000276:immunology / Q000473:pathology / Q000662:veterinary*; D002908:Chronic Disease; D004195:Disease Models, Animal; D005260:Female; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D015994:Incidence; D007700:Kinetics; D008297:Male; D051379:Mice / Q000276:immunology*; D009928:Organ Specificity; D012376:Rodent Diseases / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D013290:Streptococcal Infections / Q000150:complications / Q000276:immunology / Q000473:pathology / Q000662:veterinary*; D013292:Streptococcus agalactiae / Q000254:growth & development / Q000276:immunology / Q000472:pathogenicity*
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007075:Immunoglobulin M